Eternity Healthcare Initiates Clinical Trial in Fertility Drug Application Comparing Needle-free Injection System Against Standard Needle Use Injections

PHOENIX and VANCOUVER, British Columbia, May 5, 2014 (GLOBE NEWSWIRE) -- Eternity Healthcare Inc. (OTCBB:ETAH), a medical device and diagnostic company announced today that it has completed patient selection for the clinical trial comparing the Comfort-in™ Needle-free Injection System versus the standard needle process, for patients undergoing fertility treatments using the drug Gonadotropins.

In the clinical trial there will be 10 groups of six patients each. The clinical trial will be an open label randomized trial carried out under the supervision of a lead investigator at the Pacific Center for Reproductive Medicine. The clinical trial will not only monitor the Comfort-in™ Needle-free Injection System's ability to deliver the same quantity of drugs to the patients as the regular needle, but will observe the patients pain trauma, along with a physiological observation.

The clinical trial will involve women patients that require stimulation by the fertility drug Gonadotropins for their first superovulation cycle. Gonadotropin is a fertility drug that contains follicle stimulation hormone (FSH), luteinizing hormone (LH) or a combination of the two drugs. Gonadotropin is a natural hormone already in a woman's body that plays a role in the production of eggs and eventual ovulation. This natural hormone Gonadotropins may be used on its own or as a part of an IUI treatment or IVF treatment cycle. Synthetic gonadotropins and analogs are marketed by major pharmaceutical companies such as Astra Zeneca, Sanofi Aventis, Bayer AG, Pfizer and Abbott Laboratories, etc.

Dr. Hassan Salari stated that: "The goal of this clinical trial is to provide patients with a convenient noninvasive alternative approach for injecting the fertility drugs." He went on to state: "Some patients go though physiological pain and trauma using needles for the injection of medication. The Comfort-in™ Needle-free Injection System will provide an alternative to the inconvenient and extremely painful process of medication dispensation."

About Eternity Healthcare Inc.
(OTCBB:ETAH)

Eternity Healthcare Inc. is a medical device and diagnostic company with state of the art technologies to address human medical needs. Certain products of the Company have completed their prototype testing and received approval for sale and marketing, while several other products are still under development. For more information on the Company, please visit the Company website at www.eternityhealthcare.com.

Safe Harbor Statement

This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

CONTACT: Company contact: Lena Kuang Executive Assistant (855) 324-1110 info@eternityhealthcare.com Investor Relations Contact: Bryan Andrews Wall Street Media Group Inc. (480) 588-8658 info@wallstreetmediagroup.comSource:Eternity Healthcare, Inc.